Megestrol acetate soft capsules

This product is a semi-synthetic progesterone derivative, which has a certain inhibitory effect on hormone-dependent tumors. Its mechanism of action is the same as that of medroxyprogesterone, which may be through the influence of pituitary gonadotropin secretion, controlling the development and growth of ovarian follicles, thereby reducing the production of estrogen. It acts on estrogen receptors, preventing their synthesis and reuse, interfering with their binding with estrogen, and inhibiting tumor cell growth. In addition, it can also antagonize glucocorticoid receptors and interfere with the interaction between steroid hormone receptors and regulatory proteins related to cell growth and differentiation.

The main ingredient of this product is megestrol acetate. Chemical name: 6-methyl-17α-hydroxypregnane-4,6-diene-3,20-dione-17-acetate. Chemical structure: Molecular formula: C24H32O4 Molecular weight: 384.52

This product is a brown-red soft capsule containing an oily suspension.

For oral contraception in women.

Breast cancer: 160 mg (4 tablets)/day (taken once or divided into several doses); Endometrial cancer: 40-320 mg (1-8 tablets)/day (taken once or divided into several doses); General dose: 160 mg (4 tablets) each time, orally, once a day; High dose: 160 mg (4 tablets) each time, orally, 2-4 times a day.

Similar to other progesterone drugs, but generally milder. Weight gain is a common adverse reaction of this product, which is caused by an increase in body fat and body cell volume, and is not necessarily accompanied by fluid retention. For patients with advanced cancer cachexia and weight loss, this side effect is often beneficial. Thromboembolic phenomena have been rarely reported, including thrombophlebitis and pulmonary embolism. Other reactions can cause breast pain, galactorrhea, vaginal bleeding, menstrual disorders, and facial flushing. There are also adrenal cortisol effects, moon face, hypertension, and hyperglycemia. The incidence of uterine bleeding is 1-2%. Nausea and vomiting are occasionally seen. Rare reactions such as dyspnea, heart failure, and rash.

It is contraindicated for patients with breast cancer, reproductive organ cancer, abnormal liver function or recent history of liver disease or jaundice, deep vein thrombosis and cerebrovascular accident, hypertension, cardiovascular disease, diabetes, hyperlipidemia and depression, and women over 40 years old.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: Because the use of progesterone drugs in the first four months of pregnancy has potential harm to the fetus, this drug is not recommended. This product has potential toxic effects on newborns, and breastfeeding women should stop breastfeeding during medication. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

Not yet clear.

Keep away from light and store in sealed container.

40mg

24 months

Zhejiang Anbao Pharmaceutical Co., Ltd.

• Founded in:

  1996-12-19

• Address:

  Ningbo Economic and Technological Development Zone C1

• Tax NO.:

  9133020625643067X0

• Registered Funds:

  51.78 million yuan

• Website:

  Log in to view

• Email:

  Log in to view